Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03639610 · MORE INFO

Limitations, agreements, and source contact

PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function · Source last updated 2023-03-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
Between-group comparisons were not performed in this study due the small number of patients in each cohort, as well as differences with regards to some baseline characteristics.
point Of Contact
email
trials@oncopeptides.com
organization
Oncopeptides AB
phone
+46 8 615 20 40
title
VP Chief Operating Officer
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
Between-group comparisons were not performed in this study due the small number of patients in each cohort, as well as differences with regards to some baseline characteristics.
point Of Contact
email
trials@oncopeptides.com
organization
Oncopeptides AB
phone
+46 8 615 20 40
title
VP Chief Operating Officer

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice